Topical betulinic acid for treatment of equine melanoma and sarcoid.

Overview

• This study evaluated whether a topical 1% betulinic acid cream is safe and effective for treating equine melanoma and sarcoid skin tumors.
• The research was a randomized, double-blinded, placebo-controlled clinical trial with treated horses monitored for changes in tumor size over 30 days.

Background

• Betulinic acid is a natural compound known as a pentacyclic triterpenoid.
• It has shown anti-inflammatory and anti-tumor effects in laboratory (in vitro) studies, particularly against equine melanoma and sarcoid cells.
• However, prior to this study, there was limited evidence on its effectiveness in live horses (in vivo).

Study Objective

• To assess the safety and clinical efficacy of a compounded topical 1% betulinic acid cream in treating equine cutaneous melanoma and sarcoid tumors.
• To compare the tumor response in treated horses with those receiving a placebo cream.

Methods

• Study Design: Prospective, randomized, double-blinded, placebo-controlled clinical trial.
• Subjects: 37 client-owned horses diagnosed with either melanoma (16 horses) or sarcoid tumors (21 horses).
• Treatment Regimen:
  • 1% betulinic acid cream or placebo cream applied topically twice daily for 7 days.
  • Followed by once daily application for 21 days (total 30-day treatment period).
• Data Collection:
  • Tumor measurements and photographs were taken before and after treatment.
  • Tumor volume was calculated using standard morphometric techniques.
  • Owners completed daily questionnaires to report any adverse events.
• Data Analysis:
  • A linear mixed-effects model was used, including treatment group and tumor type as fixed effects and individual horses as a random effect.

Results

• Tumor Volume:
  • No statistically significant difference in tumor volume reduction was found between the betulinic acid group and the placebo group for either melanoma or sarcoid tumors.
  • However, some reduction in tumor volume was observed in individual horses across all groups, indicating some variability in tumor behavior.
• Safety:
  • The topical 1% betulinic acid cream was well tolerated.
  • Only mild, self-limiting local reactions were reported, with no serious adverse effects documented.

Conclusions

• The use of topical 1% betulinic acid cream for 30 days in horses with melanoma or sarcoid was safe but did not yield a statistically significant reduction in tumor size compared to placebo.
• The findings suggest that longer treatment periods or different dosing strategies might be required to achieve clinical benefit.
• Further research is needed to explore extended treatment protocols and optimize the formulation, dose, or application schedule to improve therapeutic outcomes.